Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Enhancement of rTMS for Refractory Depression
NCT04352621Phase 4Unknown
- Sponsor
- University of Cincinnati
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by University of Cincinnati. Primary endpoint: Inventory for Depressive Symptomatology - Self-Rated at 42 days. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04352621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352621.